IPO - Citius Pharmaceuticals, Inc.

Form Type: 424B5

Filing Date: 2025-06-11

Corporate Action: Ipo

Type: New

Accession Number: 000121390025053274

Filing Summary: Citius Pharmaceuticals, Inc. is offering 540,000 shares of common stock and warrants to purchase additional shares at a price of $1.22 per share. The offering includes pre-funded warrants and common warrants, with proceeds expected to be approximately $5.58 million before expenses. The offering is being conducted through H.C. Wainwright & Co., LLC, and the closing is anticipated on June 11, 2025, subject to customary conditions. This follows a recent amendment to increase the authorized shares from 26,000,000 to 260,000,000. The company has faced compliance issues with Nasdaq regarding minimum bid price requirements and has appealed the determination. The document highlights key product developments, including the anticipated launch of LYMPHIR, a product acquired through a licensing agreement, and provides details on ongoing clinical trials for its products, notably Mino-Lok, focused on central venous catheter infections.

Form Type: 424B5

Filing Date: 2025-04-02

Corporate Action: Ipo

Type: New

Accession Number: 000121390025027540

Filing Summary: Citius Pharmaceuticals, Inc. is offering 465,000 shares of common stock and pre-funded warrants to purchase up to 1,274,131 shares of common stock at a purchase price of $1.15 per share and $1.1499 per pre-funded warrant. The company anticipates that delivery of the shares and warrants will take place on or about April 2, 2025. The offering is conducted under a shelf registration process with total gross proceeds expected to be up to $250,000,000. The company has engaged H.C. Wainwright & Co., LLC as the placement agent, who will receive a cash fee equal to 7.0% of the gross proceeds. Citius Pharmaceuticals develops first-in-class critical care products and has focused efforts on three proprietary products: Mino-Lok, Halo-Lido, and NoveCite. Recent developments include the FDA approval of LYMPHIR, expected to be launched in the second quarter of 2025. Investing in these securities involves high risks, and detailed risk factors are outlined in the document, urging careful consideration before investing.